Tenaya Therapeutics, Inc.
$0.79
+1.6%Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM). It is also developing TN-401, an AAV-based gene therapy that addresses genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) caused by plakophilin 2 (PKP2) gene mutations; an AAV-based gene therapy designed to deliver the dwarf open reading frame (DWORF) gene in the heart for DCM; and Reprogramming program, an AAV-based approach for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco, California.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -1.3).
Valuation inputs: P/E -1.3, earnings yield N/A, momentum +1.6%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -73.5%, ROIC -69.4%).
Profitability stack: net margin 0.0%, ROE -73.5%, ROIC -69.4%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +16.1%, momentum +1.6%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Tenaya Therapeutics, Inc. Market vs Earnings Trajectory
Loading price and EPS data...
Tenaya Therapeutics, Inc. Fair Value Envelope
No Revenue Data
TNYA has not reported any revenue values in the available annual periods.
Tenaya Therapeutics, Inc. Profit Bridge
Profitability Analysis
No Gross Profit Margin Data
TNYA has not reported any gross profit margin values in the available annual periods.
No Operating Profit Margin Data
TNYA has not reported any operating profit margin values in the available annual periods.
No Net Profit Margin Data
TNYA has not reported any net profit margin values in the available annual periods.
Tenaya Therapeutics, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Moderate conversion rate. Some gap between earnings and cash flow may warrant investigation into working capital or non-cash items.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Tenaya Therapeutics, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Tenaya Therapeutics, Inc. Street Expectations Map
Wall Street analysts project that TNYA stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 2.33, with estimates ranging from a low of 2.00 to a high of 3.00.
The consensus 1-year price target stands at 2.33, with estimates ranging from a low of 2.00 to a high of 3.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
Mixed analyst views. Wide target range suggests differing opinions on key value drivers, growth prospects, or risk factors.
Analyst Conviction
Neutral sentiment. Fair value pricing with moderate agreement suggests wait-and-see approach or catalyst-driven opportunity.
Market Sentiment Insight
Monitor and evaluate: Current analyst consensus suggests limited conviction or near-term catalysts. Stay informed on company developments and reassess positioning as new information emerges.
Tenaya Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have sold $659K worth of TNYA shares, with no buying activity reported.
3 Months
0
0.00
8.0K
6.34K
-6K
-$6K
3-6 Months
0
0.00
972.2K
631.75K
-632K
-$632K
6-9 Months
0
0.00
7.4K
9.80K
-10K
-$10K
9-12 Months
0
0.00
8.5K
10.62K
-11K
-$11K
Top Buyers
No buying activity
Top Sellers
Column Group Iii Gp, Lp
10 Percent Owner
$631K
Ali Faraz
Director, Officer: Chief Executive Officer
$13K
Tingley Whittemore
Officer: Chief Medical Officer
$9K
Higa Tomohiro
Officer: Svp, Finance
$6K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $659K net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
4 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
No Dividend Yield Data
TNYA has not reported any dividend yield values in the available annual periods.
tnya Dividend History
Learning Layer
Related Guides
Build conviction on TNYA by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.